Abstract
The pathophysiological mechanisms underlying depression are still poorly understood. An initial hypothesis postulated to explain the substrates of depression was based on the involvement of monoaminergic systems. This early theory was proposed from different findings obtained using pharmacological tools and can explain the mechanism of action of the drugs currently used to treat depression. However, more recent studies have revealed that other neurobiological processes different from monoamines also participate in the substrates of depression. These mechanisms include the participation of several neuromodulatory systems, stress-related circuits and neuroplastic changes that could represent a direct substrate for these pathophysiological processes. The lack of selective pharmacological tools for several of these potential targets of depression represents an important limitation to study their potential involvement. In the last two decades, different lines of genetically modified mice have been generated with selective deletions in specific genes related to the control of emotional responses. This review summarizes the main findings that have been obtained with these novel genetic tools to clarify the neurobiological substrates of depression. A particular focus has been devoted to the advances obtained with mice deficient in specific components of the monoaminergic, opioid and cannabinoid system and those with mutations in elements of the hypothalamic-pituitaryadrenal axis.
Keywords: Knockout mice, mutants, behavioural models, mood disorders, dopamine, serotonin, noradrenaline, endocannabinoids, opioids, HPA, GABA, glutamate, CRF.
Current Pharmaceutical Design
Title:Genetically Modified Mice as Tools to Understand the Neurobiological Substrates of Depression
Volume: 20 Issue: 23
Author(s): Patricia Robledo, Elena Martín-Garcia, Ester Aso and Rafael Maldonado
Affiliation:
Keywords: Knockout mice, mutants, behavioural models, mood disorders, dopamine, serotonin, noradrenaline, endocannabinoids, opioids, HPA, GABA, glutamate, CRF.
Abstract: The pathophysiological mechanisms underlying depression are still poorly understood. An initial hypothesis postulated to explain the substrates of depression was based on the involvement of monoaminergic systems. This early theory was proposed from different findings obtained using pharmacological tools and can explain the mechanism of action of the drugs currently used to treat depression. However, more recent studies have revealed that other neurobiological processes different from monoamines also participate in the substrates of depression. These mechanisms include the participation of several neuromodulatory systems, stress-related circuits and neuroplastic changes that could represent a direct substrate for these pathophysiological processes. The lack of selective pharmacological tools for several of these potential targets of depression represents an important limitation to study their potential involvement. In the last two decades, different lines of genetically modified mice have been generated with selective deletions in specific genes related to the control of emotional responses. This review summarizes the main findings that have been obtained with these novel genetic tools to clarify the neurobiological substrates of depression. A particular focus has been devoted to the advances obtained with mice deficient in specific components of the monoaminergic, opioid and cannabinoid system and those with mutations in elements of the hypothalamic-pituitaryadrenal axis.
Export Options
About this article
Cite this article as:
Robledo Patricia, Martín-Garcia Elena, Aso Ester and Maldonado Rafael, Genetically Modified Mice as Tools to Understand the Neurobiological Substrates of Depression, Current Pharmaceutical Design 2014; 20 (23) . https://dx.doi.org/10.2174/13816128113196660741
DOI https://dx.doi.org/10.2174/13816128113196660741 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Development and Optimization of Ramipril Solid Lipid Nanoparticles Using Solvent Emulsification and Evaporation Method
Nanoscience & Nanotechnology-Asia Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease
Current Pharmaceutical Design GHB, GBL and 1,4-BD Addiction
Current Pharmaceutical Design Uteroplacental Circulation and Fetal Vascular Function and Development
Current Vascular Pharmacology Selection Criteria for Probiotics and Potential of Cereal Based Food Products as Novel Probiotic-Carriers
Current Nutrition & Food Science Quantitative Measurement of Some Physico-Chemical Parameters for the Medicinally Useful Natural Products
Letters in Drug Design & Discovery Melatonin Alleviates Pyroptosis of Retinal Neurons Following Acute Intraocular Hypertension
CNS & Neurological Disorders - Drug Targets The Main Receptors Involved in the COVID-19: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Women and Schizophrenia: Sex-Based Pharmacotherapy
Current Psychiatry Reviews Anabolic Androgenic Steroids Abuse and Liver Toxicity
Mini-Reviews in Medicinal Chemistry RAAS Inhibition and Renal Protection
Current Pharmaceutical Design What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?
Current Radiopharmaceuticals Enantioselective Transfer Reaction of Phenyl to Aldehydes Using LProline- Derived Amino Alcohols as Chiral Ligands
Letters in Organic Chemistry Pharmacogenetic Studies of Psychotropic Drug-Induced Adverse Effects
Current Pharmacogenomics Tityus serrulatus Scorpion Venom and Toxins: An Overview
Protein & Peptide Letters Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Current Vascular Pharmacology Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: A New Cause of Hypertension
Current Hypertension Reviews Chemical and Physical Aspects of the Edible Fractions and Seeds of Jamelao (Syzygium cumini, L. Skeels)
The Natural Products Journal Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets